In 2013, another classification has been drawn up by the Cancer Genome Atlas (TCGA) that stratified endometrial carcinoma into four prognostic molecular subgroups: POLE/ultramutated (POLE); microsatellite-instable/hypermutated (MSI); copy-number-low/TP53-wild-type (CNL), conceptually similar to “type I” endometrial carcinoma; and copy-number-high/TP53-mutant (CNH), which is similar to “type II” endometrial carcinoma, particularly to serous subtypes [18]. Here, TP53 is linked to endometrial carcinoma.